Urien S, Bastian G, Lucas C, Bizzari J P, Tillement J P
Laboratoire de Pharmacologie, Faculté de Médecine, Université Paris XII, France.
Invest New Drugs. 1992 Nov;10(4):263-8. doi: 10.1007/BF00944179.
The interactions of S12363 with human plasma proteins have been investigated in vitro by an erythrocyte partitioning technique that allows a quantitative estimation of the plasma and erythrocytes binding. S12363 was 85-95% plasma-bound and 97-98% blood-bound. The main binding protein in plasma was alpha-acid glycoprotein, with a binding constant of 0.6 x 10(6) M-1, accounting for 70% of total S12363 in plasma. Owing to extensive binding to platelets (40-50% of total blood amount), S12363 was mainly distributed in the non plasma blood compartment, with blood-to-plasma concentrations ratio of 1.2-1.4. These results indicate that, in vivo, the fraction of blood S12363 available for tissue diffusion, i.e., the free drug fraction in blood, should depend on both alpha 1-acid glycoprotein concentration in plasma and blood platelet count.
通过红细胞分配技术在体外研究了S12363与人血浆蛋白的相互作用,该技术可对血浆和红细胞结合进行定量估计。S12363与血浆的结合率为85 - 95%,与血液的结合率为97 - 98%。血浆中的主要结合蛋白是α-酸性糖蛋白,结合常数为0.6×10⁶ M⁻¹,占血浆中S12363总量的70%。由于与血小板的广泛结合(占全血量的40 - 50%),S12363主要分布在非血浆血液部分,血药浓度与血浆浓度之比为1.2 - 1.4。这些结果表明,在体内,可用于组织扩散的血液中S12363的比例,即血液中的游离药物比例,应取决于血浆中α1-酸性糖蛋白的浓度和血小板计数。